Univercells launched a new bioprocess subsidiary—Univercells Technologies—which will focus on the commercialization of the product portfolio and will explore new technology developments to expand its position in the cell and gene therapy market, according to Mathias Garny, general manager.
“With the scale-X™ bioreactor portfolio and the NevoLine™ biomanufacturing platform, designed and commercially validated by Univercells, the company experiences today a turning point,” he said. “The commercialization of these cutting-edge technologies under a dedicated brand will boost the expansion of our market reach to support advances in cell and gene therapy manufacturing.”
Hundreds of cell and gene therapies are entering clinical trials but commercial progress remains stunted by manufacturing solutions inducing capacity and reproducibility constraints when facing process scaleup, explained Garny, adding that the company will offer the scale-X bioreactor portfolio and the NevoLine platform to cell and gene therapy manufacturers. The technology portfolio is equally suited to allow mass production of human and veterinary vaccines, he noted.
“After years of innovative thinking we are proud to accelerate the commercialization of our intensified biomanufacturing technologies. They offer high-performing production capacities in a low-footprint while significantly reducing capital and operational costs. Univercells Technologies ambitions to support cell and gene therapy manufacturers in accelerating their developments and facilitating scalability from clinical phases to commercial manufacturing,” said José Castillo, CTO of Univercells Technologies.